Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 6.2….Pembrolizumab may be offered to patients with PD-L1–positive recurrent or metastatic salivary gland cancer

Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.

...Frequency of MTAP loss`Degree of PDL1 expression using formalin-fixed tumor samples`Expression of thymidylate synthase...

Twenty-six patients with PD-L1-positive SGC were enrolled and treated...Confirmed objective response rate after median follow-up of 20 months was 12%...with 3 patients achieving partial response; there were no complete responses....Pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, PD-L1-positive SGC.